These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19997710)

  • 21. Cutaneous sarcoidosis limited to scars following pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Perez-Gala S; Delgado-Jimenez Y; Goiriz R; Fernandez-Herrera J; Fraga J; Garcia-Diez A
    J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):393-4. PubMed ID: 17309467
    [No Abstract]   [Full Text] [Related]  

  • 22. Skin necrosis after injection of PEG-interferon alpha2b in an HCV-infected patient.
    Sparsa A; Loustaud-Ratti V; Alain S; Liozon E; Bédane C; Vidal E
    Acta Derm Venereol; 2004; 84(5):415-6. PubMed ID: 15503367
    [No Abstract]   [Full Text] [Related]  

  • 23. Papular Sarcoidosis of the Knees Following Treatment with Interferon Alpha and Ribavirin in a Woman with Hepatitis C.
    Monteagudo B; Grueiro MC; Vilas-Sueiro A; Campo-Cerecedo F
    Actas Dermosifiliogr (Engl Ed); 2019 Dec; 110(10):871-873. PubMed ID: 31387690
    [No Abstract]   [Full Text] [Related]  

  • 24. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

  • 25. Injection site with generalized rash caused by pegylated interferon alpha 2a injection.
    Kawada K; Maeda N; Kobayashi S; Sowa J; Tsuruta D; Kawada N
    Dermatology; 2006; 212(1):82-3. PubMed ID: 16319482
    [No Abstract]   [Full Text] [Related]  

  • 26. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
    Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sarcoidosis occurring after interferon-alpha therapy for chronic hepatitis C: report of two cases.
    Hirano A; Kataoka M; Nakata Y; Takeda K; Kamao T; Hiramatsu J; Kimura G; Tanimoto Y; Kanehiro A; Tanimoto M
    Respirology; 2005 Sep; 10(4):529-34. PubMed ID: 16135180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases.
    Descamps V; Landry J; Francès C; Marinho E; Ratziu V; Chosidow O
    Dermatology; 2008; 217(1):81-4. PubMed ID: 18446029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschr Med; 2004 Mar; 146(13):58. PubMed ID: 15219135
    [No Abstract]   [Full Text] [Related]  

  • 33. Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for Hepatitis C.
    Yan KK; Dinihan I; Freiman J; Zekry A
    Intern Med J; 2008 Mar; 38(3):207-10. PubMed ID: 18290816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term treatment with interferon-alpha can induce sarcoidosis. The connection can be stronger than earlier believed].
    Grunewald J; Andersson O; Berlin M; Bradley M; Zetterberg G; Weiland O; Eklund A
    Lakartidningen; 2006 Jun 28-Jul 11; 103(26-27):2045-8. PubMed ID: 16881277
    [No Abstract]   [Full Text] [Related]  

  • 35. Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
    Shinohara MM; Davis C; Olerud J
    J Drugs Dermatol; 2009 Sep; 8(9):870-2. PubMed ID: 19746680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A levitating tattoo in a hepatitis C patient on treatment.
    Atluri D; Iduru S; Veluru C; Mullen K
    Liver Int; 2010 Apr; 30(4):583-4. PubMed ID: 20015152
    [No Abstract]   [Full Text] [Related]  

  • 38. Multisystemic sarcoidosis associated with a second therapy for chronic hepatitis C.
    Froidure A; Horsmans Y; Lefebvre C
    Acta Gastroenterol Belg; 2009; 72(2):249-51. PubMed ID: 19637783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adverse reactions of different treatments in chronic hepatitis C].
    Luca C; Grigore L; Vâţă A; Dorobăţ C
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):991-5. PubMed ID: 20191864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Devices for the safe performance of self-injection of interferon therapy for chronic hepatitis C].
    Kurihara T; Mikata R; Yokosuka O
    Nihon Rinsho; 2006 Jul; 64(7):1368-73. PubMed ID: 16838658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.